End-of-day quote
Shanghai S.E.
23:00:00 12/05/2024 BST
|
5-day change
|
1st Jan Change
|
36.95
CNY
|
-1.83%
|
|
+4.50%
|
-45.96%
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,618
|
18,612
|
9,209
|
4,976
|
-
|
Enterprise Value (EV)
1 |
3,618
|
18,612
|
9,209
|
4,976
|
4,976
|
P/E ratio
|
54.7
x
|
51.2
x
|
-263
x
|
21
x
|
16.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.06
x
|
-
|
6.74
x
|
2.46
x
|
2.06
x
|
EV / Revenue
|
8.06
x
|
-
|
6.74
x
|
2.46
x
|
2.06
x
|
EV / EBITDA
|
38,576,621
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.64
x
|
-
|
3.67
x
|
1.68
x
|
1.54
x
|
Nbr of stocks (in thousands)
|
121,520
|
121,823
|
134,673
|
134,673
|
-
|
Reference price
2 |
29.77
|
152.8
|
68.38
|
36.95
|
36.95
|
Announcement Date
|
25/02/20
|
20/02/23
|
23/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
448.9
|
-
|
1,366
|
2,025
|
2,421
|
EBITDA
|
93.78
|
-
|
-
|
-
|
-
|
EBIT
1 |
77.3
|
-
|
-53.2
|
257
|
321
|
Operating Margin
|
17.22%
|
-
|
-3.9%
|
12.69%
|
13.26%
|
Earnings before Tax (EBT)
1 |
76.97
|
-
|
-59.1
|
255
|
319
|
Net income
1 |
66.16
|
362.9
|
-33.21
|
236
|
298
|
Net margin
|
14.74%
|
-
|
-2.43%
|
11.65%
|
12.31%
|
EPS
2 |
0.5444
|
2.986
|
-0.2600
|
1.760
|
2.210
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
20/02/23
|
23/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
8.65%
|
-
|
-1.75%
|
8%
|
9.2%
|
ROA (Net income/ Total Assets)
|
7.23%
|
-
|
-
|
-
|
-
|
Assets
1 |
915.7
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
8.170
|
-
|
18.60
|
21.90
|
24.00
|
Cash Flow per Share
2 |
0.4800
|
-
|
0.2500
|
1.910
|
2.870
|
Capex
|
97.4
|
-
|
-
|
-
|
-
|
Capex / Sales
|
21.69%
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
20/02/23
|
23/04/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -45.96% | 702M | | +4.82% | 109B | | +10.72% | 105B | | -0.38% | 22.25B | | -12.02% | 22.09B | | -7.66% | 18.68B | | -36.52% | 17.58B | | -9.21% | 16.85B | | +4.58% | 13.76B | | +34.93% | 12.46B |
Bio Therapeutic Drugs
|